# Leveraging EEG for Antidepressant Prediction With Sertraline and Escitalopram

> **NCT04388202** · PHASE4 · WITHDRAWN · sponsor: **Alto Neuroscience**

## Conditions studied

- Major Depressive Disorder

## Interventions

- **DRUG:** Sertraline
- **DRUG:** Escitalopram

## Key facts

- **NCT ID:** NCT04388202
- **Lead sponsor:** Alto Neuroscience
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2020-10-15
- **Primary completion:** 2023-05-30
- **Final completion:** 2023-05-30
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** No participants enrolled
- **Last updated:** 2020-10-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04388202

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04388202, "Leveraging EEG for Antidepressant Prediction With Sertraline and Escitalopram". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04388202. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*